TITLE:
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

CONDITION:
Mycoses

INTERVENTION:
Fluconazole

SUMMARY:

      To compare the efficacy of fluconazole versus placebo in preventing the development of
      active coccidioidomycosis and other systemic fungal infections among HIV-infected patients
      with CD4 lymphocyte counts < 250 cells/mm3 who are living in the coccidioidal endemic area.
    

DETAILED DESCRIPTION:

      Patients are randomized to receive either fluconazole or placebo daily.
    

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Documented HIV infection.

          -  CD4 count < 250 cells/mm3.

          -  No active coccidioidomycosis or other fungal disease requiring systemic antifungal
             therapy.

          -  Residence in area considered to be endemic for Coccidioides immitis.

          -  Consent of parent or guardian if under legal age of consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Unable to take oral medication.

          -  Positive serum cryptococcal antigen.

        Concurrent Medication:

        Excluded:

          -  Systemic antifungal therapy.

        Patients with the following prior conditions are excluded:

        History of hypersensitivity to azole or imidazole compounds.

        Prior Medication:

        Excluded:

          -  Systemic antifungal agents within 2 weeks prior to study entry.
      
